Daaweynta laba-geesoodka ah ee BIOOCUS Medical Group waxay soo bandhigaysaa natiijooyin rajo leh oo ku saabsan Myasthenia Gravis oo aan fiicnayn: Safarka Bukaanka Da'da yar
Myasthenia Gravis (MG) waa xanuun daba-dheeraada oo neerfaha muruqyada ah oo ay keento unugyada difaaca jirka ee iswada (oo inta badan ka hortagaya unugyada soo dhaweeyaha ee ka hortagga acetylcholine, AchRAb) kaas oo wiiqa isgaarsiinta neerfaha iyo murqaha, taasoo keenta daciifnimo isbeddelaysa, ptosis, dysphagia, iyo xaaladaha daran ee neefsashada oo halis gelinaysa nolosha. Bukaannada qaba MG aan firfircoonayn oo aan ka jawaabin daawooyinka difaaca jirka ee caadiga ah, IVIG, FcRn inhibitors, ama daawooyinka ka hortagga, fursadaha daaweynta ayaa xaddidan - ilaa hadda.
Daaweynta laba-bartilmaameedka CD19/BCMA CAR-T ee BIOOCUS Medical Group waxay u taagan tahay daaweyn unug oo otomaatig ah oo horumarsan oo si sax ah u baabi'isa unugyada B ee cudurada keena iyo unugyada balaasmaha ee mas'uulka ka ah soo saarista unugyada difaaca jirka. Habkan laba-bartilmaameedka ah wuxuu bixiyaa suurtagalnimada cafis qoto dheer oo waara iyadoo wax laga qabanayo qaybaha unugyada iyo kuwa humoral ee jawaabta isdifaaca jirka.
Kiis matalaad ah ayaa iftiiminaya ballanqaadka daaweynta. Bukaan dumar ah oo 20 jir ah, oo loo yaqaan LYN, ayaa lagu ogaaday inay qabto Myasthenia Gravis (CNGIIIa, AchRAb-positive) iyo thymoma/thymic hyperplasia nooca qalliinka ka dib B3. Waxay sidoo kale lahayd cudurro ay ka mid yihiin lafo-beelka, madaxa femoral-ka ee laba-geesoodka ah iyo necrosis-ka bidix ee 'proximal tibial avascular necrosis', iyo dhiig-yaraanta birta. Iyadoo ay jiraan dhowr daaweyn laga bilaabo 2019 ilaa 2025 - oo ay ku jiraan steroids-ka qiyaasta sare leh iyo azathioprine, tacrolimus, cyclosporine, IVIG soo noqnoqda, efgartigimod, eculizumab iyo telitaccept, iyo rituximab (500 mg) - xaaladdeeda wali lama xakamayn.
Bishii Nofeembar 2025, hab-raaca CAR-T ayaa la bilaabay, cyclosporine-na waa la joojiyay. Unugyada dhiigga ee mononuclear-ka ee ku wareegsan ayaa la ururiyay Diseembar 1, 2025. Diseembar 15, 2025, waxay heshay faleebo CD19 CAR-T (0.5×10⁶/kg) oo lagu daray BCMA CAR-T (1×10⁶/kg). Wax dhibaato ah lama arag faleebo kadib.
Bishii Maarso 2026, qiimeynta dabagalka ayaa muujisay koror degdeg ah oo ku yimid CAR-T, iyadoo heerka ugu sarreeya ee CD19 CAR-T uu ahaa maalintii 10aad (7.62%, 4.622×10⁷/L) iyo BCMA CAR-T uu ahaa maalintii 10aad (17.17%, 1.0414×10⁸/L), oo la sii waday ilaa bishii 3aad. Horumarinta shaybaarka waxaa ka mid ahaa hoos u dhac weyn oo ku yimid heerarka AchRAb iyo tirada guud ee B-lymphocyte, iyadoo tirada dhiigga oo deggan, shaqada beerka iyo kelyaha. Caafimaad ahaan, guulo la taaban karo ayaa laga diiwaan geliyay dhibcaha Quantitative Myasthenia Gravis (QMG) iyo Activitys of Daily Living (ADL). Calaamadaha sida diplopia, adkaanta wejiga, dysarthria, iyo daalka addimada ayaa muujiyay xal ama horumar la taaban karo.
Kiiskan wuxuu muujinayaa awoodda isbeddelka ee daaweynta laba-bartilmaameed ee BIOOCUS Medical Group ee CD19/BCMA CAR-T ee ku aaddan gaarista dib-u-dejinta difaaca jirka ee qoto dheer iyo faa'iido caafimaad oo macno leh oo ku jirta MG-ga aan firfircoonayn. Daaweyntu si fiican ayay u dulqaadanaysaa, iyada oo aan la arag CRS ama sunta neerfaha, waxayna ballan qaadaysaa cafis muddo dheer ah iyadoo la dhimayo baahida loo qabo xakamaynta difaaca jirka ee daba-dheeraatay.